Cytoskeletal alteration modulates cancer cell invasion through RhoA-YAP signaling in stromal fibroblasts

Do Kyeong Kim¹,², Eun Kyoung Kim¹, Da-Woon Jung³, Jin Kim¹*¹

¹ Oral Cancer Research Institute, Department of Oral Pathology, BK21 PLUS Project, Yonsei University College of Dentistry, Seoul, Republic of Korea, ² Department of Dental Hygiene, Jeonju Kijeon College, Jeonju, Republic of Korea, ³ New Drug Targets Laboratory, School of Life Sciences, Gwangju Institute of Science and Technology, 1 Oryong-dong, Gwangju, Republic of Korea

* jink@yuhs.ac

Abstract

Cancer-associated fibroblasts (CAFs) participate in carcinogenesis through interaction with cancer cells. This study aimed to investigate the mechanism of cytoskeletal alteration of CAFs and its role in invasion of oral squamous cell carcinoma (OSCC). Immortalized normal fibroblasts (hTERT-hNOFs) co-cultured with OSCC cells showed myofibroblastic and senescent phenotypes like CAFs. Thus, this study substituted hTERT-hNOFs for CAFs. Next, the cytoskeletal alteration and its molecular mechanism were investigated in hTERT-hNOFs co-cultured with OSCC. As results, we found that RhoA regulated cytoskeletal organization in fibroblasts surrounding OSCC cells. Furthermore, as a downstream transcriptional factor of RhoA, YAP was mainly localized in the nucleus of hTERT-hNOFs co-cultured with OSCC. Consequently, we examined whether nuclear YAP localization of fibroblasts could influence cancer progression. YAPS127A fibroblasts manifesting nuclear localization of YAP induced cytoskeletal alteration and increased gel contractility and matrix stiffness, and thereby enhances the invasiveness of OSCC cells. In conclusion, the modification of tumor microenvironment, such as cytoskeletal change and matrix remodeling via RhoA-YAP in CAFs, modulates OSCC invasion. These understandings will provide the development of novel approaches for CAFs-based cancer therapy.

Introduction

Carcinomas are not only composed of malignant epithelial cells, but also organized as complex with tumor microenvironment through reciprocal interaction[1]. In the tumor microenvironment, Cancer-associated fibroblasts (CAFs) are the most abundant cells that can participate in carcinogenesis[1,2], including angiogenesis[3] and metastasis[4,5].

CAFs are characterized by myofibroblastic- and senescent phenotypes[2,6,7]. The myofibroblastic phenotypic CAFs heterogeneously expressed the markers of activated fibroblasts, including α-smooth muscle actin (α-SMA), fibroblast-activation protein (FAP) and fibroblast-specific protein 1 (FSP1)[2,8]. As the characteristics of senescent fibroblasts, IL-6 and IL-8,
senescence associated secretory protein (SASP), are released from CAFs[9]. Also, oncoproteins, including Caveolin-1[10,11], CSL and p53[12] could maintain the state of senescent CAFs. Most cancer therapies have mostly focused on neoplastic epithelial cells, while little attention to CAFs.

Unlike tumor cells, CAFs are genetically stable. With these reasons, CAFs have been emerged to be an attractive therapeutic target for reducing risk of drug resistance and tumor recurrence[13–16]. Several molecules have already been suggested as promising targets of CAFs-based therapy; Targeting FAP, SDF-CXCR4, HGF-Met, TGF-β, PDGF-C and VEGF signaling pathways attenuated tumor growth and tumor progression, as well as reducing innate drug resistance[17–19]. The drugs to CAF-based therapy can partially block the function of CAFs and some of them are even in clinical trials, such as Sibrotuzumab[20] or Talabostate[21] targeting FAP and other drugs targeting TGF-β signaling[22,23]. However, there are still many limitations in clinical trial; well-known CAF markers, α-SMA and FAPα, are often without distinction from normal fibroblasts or even higher expression in normal fibroblasts[8]. In addition, these CAFs markers are detected in other non-cancerous cell type, such as pericytes and smooth muscle cells or mesodermal cells[24]. Thus, it is not enough to target CAFs specifically in clinical trials yet. Importantly, the promising molecule for CAF-based cancer therapy should be developed to improve their specificities and efficacies.

CAFs exhibited cytoskeletal changes, including forced contractility and tissues stiffness, and then increased proteolytic activity to remodel the extracellular matrix (ECM) adjacent to cancer[25,26]. Despite of the association of tissue mechanical features in cancer, the mechanical role of CAFs remains poorly understood in cancer progression. Therefore, this study aimed to investigate the cytoskeletal alteration and its molecular mechanism of CAFs, and further to examine its role in invasiveness. This study will contribute to develop novel approaches for CAFs-based cancer therapy.

Materials and methods
Reagents and antibodies
Antibodies for α-SMA (1:100, mouse monoclonal, Dako, Glostrup, Denmark), Vimentin (1:1000, rabbit monoclonal, Cell signaling technology, Beverley, MA, USA), Phospho-FAK (Tyr397) (1:1000 Cell signaling technology, Beverley, MA, USA), FAK (1:1000, rabbit monoclonal, Cell signaling technology, Beverley, MA, USA), YAP (1:200, mouse monoclonal, Santa Cruz, CA, USA), phospho-YAP (1:1000, rabbit monoclonal, Cell signaling technology, Beverley, MA, USA), Lamin B1 (1:1000, rabbit monoclonal, Cell signaling technology, Beverley, MA, USA), β-tubulin (1:1000, Cell signaling technology, Beverley, MA, USA) and β-actin (1:5000, Bioworld Technology, St. Louis, MN) were used, respectively. Horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). The pharmacological inhibitors, Y27632 and Latrunculin A (Lat. A) were obtained from Enzo Life Sciences (Farmingdale, NY), were used to block RhoA downstream kinase (ROCK) and actin polymerization, which can prevent the F-actin assembly by forming the complex between Lat. A and G-actin. For invasion assay, type I collagen (Cellmatrix type 1-A) was purchased from Nitta Gelatin (Osaka, Japan). For ELISA immunoassay, recombinant human IL-6 and IL-8 (standard), human/Primate IL-6 (2μg/ml) / IL-8 (8μg/ml) Antibody (Capture) and Human/Primate IL-6 (2.5μg/ml) / IL-8 (1μg/ml) Biotinylated Antibody (Detection) were obtained from R&D systems. For immunofluorescence, Phalloidin-Tetramethylrhodamine B isothiocyanate and diamidinoxyphotobinol (DAPI) were purchased from Sigma Aldrich (MO, USA). The cells cover-slipped with Dako fluorescent mounting medium (Dako, CA, USA).
Cell culture

The immortalized human gingival fibroblasts by hTERT-transfection (hTERT-hNOFs) were used, which is previously described [27,28]. CAFs, which were obtained from the surgical specimens of OSCC patients, and NOFs, which were derived from three patients without mucosal disease who underwent wisdom tooth extraction, were used for conducting the study. CAFs and NOFs were primary cultured in Yonsei University College of Dentistry (IRB 2-2012-0027) [19]. All fibroblasts were then maintained in F medium which is composed of Dulbecco’s modified Eagles medium (Gibco BRL, NY, USA) and F-12 Ham (Ham’s F12; Gibco BRL, NY, USA) mixed in a 3:1 ratio, and supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Normal human epidermal keratinocytes (HEK) were also used for this study and maintained in keratinocyte growth media with supplementary bullet kit (KGM; Lonza, Walkersville, MD, USA) [28]. YD10B and YD38 OSCC cells were obtained from tongue and lower gingiva of OSCC patients, respectively [29]. YD OSCC cells were maintained in EF medium (the mixture of F medium and E medium at 9:1 ratio). E medium is composed of 0.01 μg/ml cholera toxin, 0.04 μg/ml hydrocortisone, 0.5 μg/ml insulin, 0.5 μg/ml apo-transferin, and 0.2 μg/ml 3’-5-triiodo-1-thyroxine (Sigma, MO, USA) in F medium. All cells were maintained at 37˚C in an incubator containing 5% CO$_2$. The authentication of all cell lines was verified by STR DNA profiling in Korean Cell Line Bank.

RNA extraction and RT-PCR

Total RNA was extracted from each cells using RNeasy plus mini kit (Qiagen, Hilden, Germany), and cDNA was synthesized from 1 μg of the total RNA by using RT&GO-MasterMix (MP Biomedicals, CA, USA) according to the manufacturers’ protocols. The primer sequences for PCR are shown as following. IL-6; forward(F): 5’-ATGAACTCTCTTCTCCACACG-3’, reverse(R): 5’-AGAACGGCCTCAAGGTGCCAC-3’, IL-8; F: 5’-AGCACAGAGGACACACACAA GC-3’, R: 5’-TTGGGTGGAAAGCTTTGGAG-3’, FAK; F: 5’-TTGGGACGCTTTACCTAGC-3’, R: 5’-AGGGACAGGACAAATTTGG-3’, IL-8; F: 5’-TCTTACAGAAGACCAGGACCAG TTC-3’, R: 5’-CCAACTCTACTGCTCTTTCCA-3’, RhoA; F: 5’-TCTTACAGAAGACCAGGACCAG TTC-3’, R: 5’-CCAACTCTACTGCTCTTTCCA-3’, Rac1; F: 5’-GAAGGGCTAAGTGTGATGAAA-3’, YAP; F: 5’-GGTGGTCTTTCGGAACGAC-3’, CANF1; F: 5’-CTCGATGGGTGGGAGACGAA-3’, F: 5’-GGTGGTCTTTCGGAACGAC-3’, CTGF; F: 5’-ATGAACTCTCTTCTCCACACG-3’, reverse(R): 5’-ATGAACTCTCTTCTCCACACG-3’, YAP; F: 5’-GGTGGTCTTTCGGAACGAC-3’, Cdc42; F: 5’-CTCGATGGGTGGGAGACGAA-3’, R: 5’-GGTGGTCTTTCGGAACGAC-3’, CTGF; F: 5’-ATGAACTCTCTTCTCCACACG-3’, reverse(R): 5’-ATGAACTCTCTTCTCCACACG-3’, YAP; F: 5’-GGTGGTCTTTCGGAACGAC-3’, Cdc42; F: 5’-CTCGATGGGTGGGAGACGAA-3’, R: 5’-GGTGGTCTTTCGGAACGAC-3’, CTGF; F: 5’-ATGAACTCTCTTCTCCACACG-3’, reverse(R): 5’-ATGAACTCTCTTCTCCACACG-3’, YAP; F: 5’-GGTGGTCTTTCGGAACGAC-3’. The reaction mixture was subjected to 30 RT-PCR amplification cycles 40 s at 94˚C, 58 s at 48˚C and 40 s at 72˚C and the products were loaded in 1–1.5% agarose gel using StaySafe Nucleic Acid Gel Stain (Real Biotech Corporation, Taipei, Taiwan). The results of RT-PCR were normalized to GAPDH.

Enzyme linked immunosorbent assay (ELISA)

For collecting co-culturing conditioned medium, All fibroblasts (2 × 10$^5$) were grown in the lower chamber and then OSCC cells (2 × 10$^5$) were seeded in 6-transwell plates containing collagen-coated 0.4 μm pore transmembrane filters (Corning-costar, Lowell, MA, USA) for 48 h. In case of mono-culturing medium, only fibroblasts were seeded in lower chamber of 6-well plate. The mediums were collected by centrifugation, and protein concentration was estimated using Pierce BCA protein assay kit (Thermo Fisher Scientific). In briefly, capture antibodies were attached in microplates at overnight. Then, conditioned mediums and standard recombinant proteins were added and bind to capture antibodies for 2 h. After washing steps, the antibodies for detection were incubated for 1 h. After removal of excess detection antibodies, an HRP conjugate streptavidin was added and subsequently, TMB solution and H$_2$SO$_4$ solution
was added. The intensity of colored product was analyzed by M680 microplate reader (Bio-Rad). All results were normalized for total protein concentration and indicated as pg/mg of protein

**Protein extraction and Western blotting**

When fibroblasts co cultured with OSCC cells, the fibroblasts \( (2.5 \times 10^5) \) were seeded in lower chamber and then co cultured with OSCC cells or HEK cells \( (2.5 \times 10^5) \) of upper chamber in 6-well plates. In brief, cell was lysated by cell lysis buffer (Cell signaling technology, Beverly, MA, USA) and then harvested. After lysing, protein lysates were incubated for 30 min on ice with vortexing every 5 min. The lysates were centrifuged at maximum speed (>15,000 rpm) for 10 min. Subsequently, the lysates were boiled for 5 min in sodium dodecyl sulfate (SDS) sample buffer and separated on 10% SDS-PAGE. For fraction of nuclear cytoplasmic protein, NE-PER Nuclear and Cytoplasmic extraction reagents (Thermo Fisher Scientific Inc. USA) were used, respectively, according to instructions. The proteins were transferred to polyvinylidene difluoride (PVDF) membrane, blocked in 5% milk in Phosphate Buffered Saline with Tween 20 (PBST). The membranes were immunoblotted with appropriate primary antibodies and then incubated with horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies (Cell signaling technology, Beverly, MA, USA) and detection was done by chemiluminescence (GenDEPOT, TX, USA).

**Senescence-associated β-galactosidase (SA-β-Gal) staining**

In co-culturing condition, hTERT-hNOFs \( (1.5 \times 10^5) \) were seeded and incubated overnight in a 6-well lower chamber and OSCC cells \( (1.5 \times 10^5) \) or HEK cells \( (1.5 \times 10^5) \) were added in 6-well upper chamber, respectively. In mono-culturing condition, only fibroblasts were grown in 6-well plates. After indicated times, cells were stained using β-galactosidase staining kit (Cell signaling technology, Beverly, MA, USA) and incubated overnight at 37˚C without maintaining 5% CO\(_2\). The cells were washed with PBS and 70% glycerol was added for storage. Stained cells were identified and counted by light microscopy (Olympus, Tokyo, Japan).

**Immunofluorescence**

In co-culturing condition, sterilized cover glasses \( (20 \times 20 \text{ mm}, \text{ Deckglaser}) \) were put into 6-transwell plates containing collagen-coated 0.4 μm pore transmembrane filters (Corning-costar, Lowell, MA, USA). Then, fibroblasts were seeded onto cover glasses in lower chamber and OSCC cells were incubated in upper chamber for indicated times. In CAFs and NOFs, the fibroblasts were seeded into chamber slide (Lab-Tek Chamber slide, Nalge Nunc, Roskilde, Denmark). The cells were stained with appreciated antibodies (Phallodin(F-actin), YAP) following manufacturer’s instructions. The nuclei were stained with 10 μg/ml DAPI and then Dako fluorescent mounting medium was used to cover-slipped.

**RhoA-GTP pull down assay**

For measurement of RhoA activation, RhoA activation assay Kit (abcam, Cambridge, UK) was utilized by manufacturer’s instructions. In brief, the fibroblasts were harvested by 1X Assay/Lysis Buffer and then the lysates centrifugation for 10 min \( (12,000 \text{ g at 4˚C}) \). The lysates were added anti-Active RhoA mouse monoclonal antibody and subsequently incubated by gently agitating with the protein A/G agarose bead slurry for 1 h. After that, the samples were centrifugated for 1 min at 5,000 g. After washing step, 2X SDS sample buffer was added in the
bead pellet. Then, proteins were transferred to PVDF membrane. GTP gamma S was used as a positive control and GDP was used as a negative control.

**Plasmids and transfection**

pcDNA4/HisMaxB mammalian expression vector was purchased from Invitrogen (#V864-20 (43-0078F), USA). pcDNA4/HisMaxB-YAP1 (#18978) and pcDNA4/HisMaxB-YAP-S127A (#18988) were obtained from Addgene (Cambridge, MA, UK). In brief, prepared plasmids were amplified using Plasmid Plus Midi Kit (Qiagen, Hilden, Germany) and then selected by ampicillin (Sigma, MO, USA). Purified plasmid DNA was transfected using 4D-nucleofector X Kit for mammalian fibroblasts and Amaza 4D-nucleofector (Lonza, Walkersville, MD, USA), following as manufacturer's instructions. Zeocin selection reagent (#R250-01) (100 μg/ml) was used to select transfected cells. The transfection results were confirmed by DNA sequencing analysis (Bioneer, Co., Daejeon, Korea). In brief, DNA was extracted from WT-YAP-transfected and YAPS127A-transfected hTERT-hNOFs by using DNA Mini Kit (Qiagen, Hilden, Germany), and thereby RT-PCR was performed as indicated in RT-PCR method above. The following primer sequences to detect the mutation of phosphorylation site (serine at 127) in YAP; 5’ - GTGATGAACCCCAAGACG - 3' (forward) and 5’ - GGCAGAGGTACATCATCAGG - 3’ (reverse). After electrophoresis, the exact DNA fragment was cut out with a scalpel and then DNA sequencing analysis was identified from Gel DNA extraction (iNtRON, Korea). Genomic identities were confirmed using BLASTN (http://www.ncbi.nlm.nih.gov/BLAST).

**ECM-remodeling assay**

To assess the matrix remodeling mediated by fibroblasts, respectively, the fibroblasts were embedded in 500 μl of collagen Type I and seeded into. Surrounding the mixtures, F medium was added to maintain the cell. Gel contraction was monitored with the naked eye daily. After 5 days, the gel contraction value was obtained and the relative diameters of the well and the gel were measured using Image J software.

**Atomic force microscopy (AFM)**

To check the elastic modulus, the fibroblasts were embedded in collagen type I. After 3 days, the edge of gels was cut with scalpel and gently moved to cover glass. The elastic modulus of the gels was measured by using Atomic force microscopy (AFM) in Yonsei Center for Research Facilities. AFM measurements were performed with a JPK Nanowizard-I (JPK instruments) interfaced to an inverted optical microscope. Pyramidal C-AFM cantilever was used with 10 μm tip sphere. Before the experiments, the sensitivity of the cantilever was set by measuring the slope of force-distance curves on empty region of glass. Using the optical microscope, the tip of the cantilever was aligned over three regions in each gel. The data represented on the average of Young’s modulus.

**Transwell migration and invasion assay**

In transwell migration assay, OSCC cells (2 × 10^5) were seeded in Transwell cell culture chamber inserts (24-transwell plates, 8 μm pore size; Costar, Cambridge, MA) in the presence of P medium. The lower chamber contained P media supplemented with 1% FBS. After 48 h of incubation, the cells on the upper surface of the filter were removed with a cotton. The cells that had migrated to the lower compartment were fixed in 10% formalin solution and stained with 0.025% crystal violet. The membrane filters were cut and mounted on slides, and then the
cells were counted in five images per well (200x magnification). Each assay was performed in triplicate. Transwell invasion assays were performed in the same manner with transwell migration assay. Additionally, the inserts containing 8 μm pore size filters were coated with collagen Type I (45 μg/30 μL/well) and then solidified for overnight in 37˚C incubator. After hardening the collagen, OSCC cells (2×10^4) were seeded in the transwell chambers with porous filters in the upper wells. The fibroblasts in P medium containing 1% FBS was added into the lower well to induce invasive capacity of cancer cells onto upper wells. The cells that penetrated the filter were fixed, stained with 0.025% crystal violet and counted by light microscopy.

Three-dimensional (3D) raft culture
Collagen mixture was prepared by mixing eight volumes of type I collagen solution (Nitta Gelatin, Osaka, Japan), one volume of 10× reconstitution solution (0.022 g/ml NaHCO₃, 0.0477 g/ml HEPES and 0.05 N NaOH), and one volume of 10× P medium. The fibroblasts (hTERT-hNOFs and CAFs) (1.5×10^5) were mixed with 250 μl collagen mixture. The cell-collagen mixture was placed into a Mill-cell (3.0 μm pore size, 12 mm diameter; Millipore, Billerica, MA, USA) and allowed to be polymerized at 37˚C for 24 h. OSCC cells (YD10B and YD38) (3×10^5) were seeded on top of the fibroblast-collagen mixtures. The cultures were incubated for 4 days and raised to the air-liquid interphase for 14 days. The rafts were fixed, embedded in paraffin, sectioned and stained using hematoxylin and eosin.

Small interfering RNA (siRNA) transfection
YAP small interfering RNA (siRNA) had the following sense and antisense sequences: siYAP#1 (#1164680); Sense ‘CAGGAAUUGAGAACAAUGA’ and Antisense ‘UCAUUGUUCUCAA UUC CUG’, siYAP#2 (#116477); Sense ‘CAGAAGAUCAAGCUACUU’ and Antisense ‘AAGIUAG CUUGAUCUUCUG’. A negative control siRNA was used (Bioneer). Transfection of siRNA was performed using the Lipofectamine RNAiMAX (Invitrogen) according to the manufacturers’ instructions. In brief, hTERT-hNOFs (2×10^5) were seeded per well in a 6-well plate and cultured for 24 h. YAP siRNAs were diluted with 250 μl Opti-MEM (Invitrogen). These two dilution mixtures were combined, mixed gently, and incubated for 20 min at room temperature to facilitate complex formation. The 500 μl siRNA-Lipofectamine mixture was then added to cells. The transfected cells were cultured for 48 h and then assayed.

Statistical analysis
All statistical analyses were analyzed by using the SPSS version 24 (SPSS Inc., Chicago, IL, USA). Mann-Whitney U test and Student t test (Independent t test) were used to determine the statistical significant difference. All of the variables were tested in three independent
The immortalized fibroblasts co-cultured with OSCC cells harbor CAFs-like characteristics

As a substitution for CAFs, we used immortalized fibroblasts (hTERT-hNOFs) to overcome individual variation of primary cultured CAFs. First, we measured expression levels of myofibroblast differentiation markers, such as α-SMA and Vimentin. CAFs stimulated by OSCC cells showed increased α-SMA protein expression, even though the respective baseline expression level differed between CAF1 and CAF2 (Fig 1A). The expression and secretion of IL-6 and IL-8 were also increased in CAFs exposed by OSCC cells (Fig 1B and 1C). Consistently, when hTERT-hNOFs co-cultured with OSCC cells, α-SMA protein expressions were upregulated (Fig 1A). Also, hTERT-hNOFs co-cultured with OSCC cells secreted higher level of IL-6 and IL-8, as compared with mono-cultured cells (Fig 1B and 1C). We next investigated whether hTERT-hNOFs functionally promote the invasion of cancer cells in organotypic 3D culture models. Consistent with OSCC cells co-cultured with CAFs, OSCC cells co-cultured with hTERT-hNOFs invaded into stroma (Fig 1D).

Because CAFs show senescent features, we observed whether hTERT-hNOFs also possessed a senescent phenotype. When co-cultured with YD10B OSCC cells, SA-β-Gal positive cells was markedly increased in both CAFs and hTERT-hNOFs, compared to mono-cultured fibroblasts (Fig 1E). To support these results, the fractions of proliferating cells and senescent cells were measured in hTERT-hNOFs co-cultured with HEK or OSCC cells by double immunofluorescence staining with Ki67 and p16 (S1 Fig). Co-culturing hTERT-hNOFs with OSCC cells showed higher fraction of p16 positive cells and a decline of Ki67 positive cells, compared to those co-cultured with HEK. The senescent phenotypical change was induced by a variety of OSCC cells (S2A Fig), and was the specific feature of hTERT-hNOFs adjacent to OSCC, not to normal epithelium (S2B Fig). These results suggested that co-cultured hTERT-hNOFs with OSCC cells were biologically similar to CAFs. Based on these data, our experiments were conducted with hTERT-hNOFs.

Cytoskeletal alteration of CAFs adjacent to OSCC cells

To identify the cytoskeletal alteration of fibroblasts by co-culturing with OSCC cells, cell sizes were measured (region of interest, ROI). Compared with fibroblasts mono-cultured and co-cultured with HEK, the average of cell area significantly showed 1.42- and 1.27-fold increase in hTERT-hNOFs co-cultured with YD10B, and 1.52- and 1.35- fold increase in them with YD38, respectively (Fig 2A). These results indicated that fibroblasts showed larger cell size as stimulated by OSCC cells. Furthermore, primary CAFs, already stimulated by OSCC cells,
have larger cell sizes than hTERT-hNOFs, respectively. When primary CAFs were additionally grown surrounded by OSCC cells (YD10B), the average of cell size is more increased than mono-cultured CAFs (CAF#1 with YD10B, 1.79-fold increase; CAF#2 with YD10B, 1.15-fold increase), like hTERT-hNOFs co-cultured with OSCC cells (Fig 2A). The results indicate that fibroblasts have enlarged by exposure to OSCC cells.

Cytoskeletal proteins, including phalloidin, indicate cellular morphology and intracellular stress fibers[30]. To further examine intracellular phenotypical alteration, phalloidin staining was performed. F-actin assembly was increased in the hTERT-hNOFs co-cultured with OSCC cells, but not in hTERT-hNOFs mono-cultured or co-cultured with HEK (Fig 2B).

RhoA regulates cytoskeletal change of CAFs

Rho GTPase family genes related to cytoskeletal changes of CAFs[31,32]. Among them, Focal adhesion kinase (FAK) and RhoA mRNA expression were markedly upregulated in hTERT-hNOFs co-cultured with YD10B cells (Fig 3A and 3B). Out of two Rho GTPase family genes, active RhoA protein expression was increased by co-culturing with OSCC cells, not with HEK (Fig 3C). However, no evidence of FAK phosphorylation was found (Fig 3D), suggesting that the cytoskeletal alteration of fibroblasts surrounding OSCC cells occurs independently on FAK phosphorylation.

Co-cultures were treated with the RhoA kinase (ROCK) inhibitor, Y27632, to assess whether RhoA regulates cytoskeletal alterations in hTERT-hNOFs co-cultured with OSCC cells. Y27632 induced the reduction of cell size and stress fibers (Fig 3E and 3G), suggesting that RhoA-ROCK signaling regulates the cytoskeletal change of CAFs.

Nuclear localization of YAP increased in CAFs

Considering that YAP acts as a downstream of RhoA[30,33], YAP localization was identified in co-cultured hTERT-hNOFs with OSCC cells by immunofluorescence. When hTERT-hNOFs were grown alone or with HEK, YAP was mainly accumulated in cytoplasm. Conversely, YAP was mainly localized in the nucleus of the fibroblasts as co-cultured with OSCC cells (Fig 4A and 4B). To confirm these results, nuclear and cytoplasmic protein was separately extracted. Following co-culture hTERT-hNOFs with OSCC cells, the cytoplasmic expression of YAP increased 1.4-fold, whereas its nuclear expression increased 2.8-fold compared to mono-cultured cells (Fig 4C). Consistent with these results, connective tissue growth factor (CTGF), a YAP target gene, was increased in hTERT-hNOFs co-cultured with OSCC cells, compared to co-culturing with HEK cells (Fig 4D).

To further elucidate the relationship between RhoA and YAP localization or cytoskeleton and YAP localization, ROCK inhibitor (Y27362) or actin polymerization inhibitor (Lat.A) was treated. After the treatment of Y27362 or Lat.A, nuclear YAP was relocalized at cytoplasm in...
Fig 4. Nuclear accumulation of YAP was increased in CAFs. (A) All immunofluorescence microscopy experiments were performed on cultured cell after 3 days. DAPI (blue), YAP (green) and Merged staining are shown in mono-cultured hTERT-hNOFs (first panels) and hTERT-hNOFs co cultured with HEK (second panels), YD10B OSCC cell (third panels) and YD38 OSCC cell (fourth panels), Scale bar, 50µm. (B) Graph summarizing the distribution of YAP was shown. It was analyzed by Image J software program (hTERT-hNOFs mono cultured, n = 67; co cultured with HEK, n = 53; with YD10B, n = 60; with YD38, n = 61, **p < 0.001; student t test). (C) hTERT-hNOFs were grown with or without YD10B OSCC cell for indicated time. Nuclear/cytoplasmic fraction was isolated from each protein and then western blot was performed to check the YAP distribution. Lamin B1 was used as a positive control of nuclear protein fraction and β-tubulin was used as a positive control of cytoplasmic protein fraction. Nuclear/cytoplasmic YAP expression was normalized to each nuclear/cytoplasmic positive control. (D) hTERT-hNOFs were grown with OSCC cells or HEK cell for 3 days. YAP target gene, CTGF, was identified by RT-PCR. (E) All immunofluorescence microscopy experiments were performed on cultured cell after 3 days. DAPI (blue), Phalloidin (red) YAP (green) and Merged staining are shown in mono-cultured hTERT-hNOFs (first line) and hTERT-hNOFs co cultured with YD10B OSCC cell (second line), with YD10B OSCC cell + Y27362 (third line), with YD10B OSCC cell + Lat.A (fourth line), with YD38 OSCC cell (fifth line), with YD38 OSCC cell + Y27362 (six line) and with YD38 OSCC cell + Lat.A (seven line), Scale bar, 50µm. (F) Graph summarizing the distribution of YAP was shown. It was analyzed by Image J software program (mono culture, n = 26; with YD10B, n = 13; with YD10B + Y27362, n = 35; with YD10B + Lat.A, n = 38; with YD38, n = 24; with YD38 + Y27632, n = 34; with YD38 + Lat.A, n = 39) (**p < 0.001; student t test). (G) Cell size was measured by using ZEN 2012 software program. (mono culture, n = 25; with YD10B, n = 22; with YD10B + Y27362, n = 24; with YD10B + Lat.A, n = 25; with YD38, n = 26; with YD38 + Y27632, n = 24; with YD38 + Lat.A, n = 25) (*p < 0.05, **p < 0.01, ***p < 0.001; student t test).

https://doi.org/10.1371/journal.pone.0214553.g004

YAPS127A fibroblasts increase migratory and invasive activities of OSCC cells by remodeling ECM structures

EGFP was co-transfected with pcDNA4-HisMaxB (empty vector), pcDNA4-HisMaxB-YAP1 (WT) and pcDNA4-HisMaxB-YAPS127A in hTERT-hNOFs. Fluorescence microscope was used to identify the transfection of EGFP (Fig 5A). Furthermore, YAP protein expression was identified by western blot. YAPS127A-fibroblasts showed lower expression phospho-YAP (S127), which indicates cytoplasmic retention, compared with WT fibroblasts (Fig 5B). Immunofluorescent features revealed YAP nuclear localization in YAPS127A-fibroblasts, compared with WT-fibroblasts (Fig 5C). YAPS127A fibroblasts showed more enlarged cell size than WT-fibroblasts (S4B Fig). However, the intensity of phalloidin was not significant (S4A Fig). To test whether YAPS127A fibroblasts can regulate the contractility of gel, the contractility of collagen gels was measured by using their matrix remodeling capacity. Significantly, the gel of YAPS127A fibroblasts was contracted, compare with the gel of WT fibroblasts (Fig 5D), indicating that YAPS127A fibroblasts can remodel the matrix. Furthermore, the matrix stiffness showed that 1.08-1.01- fold increase in YAPS127A fibroblasts (360633.3 Pa), respectively, compared with in empty vector fibroblast (335366.7 Pa) or WT-fibroblast (356866.7 Pa) (Fig 5E).

To further evaluate whether RhoA–YAP induced cytoskeletal changes contribute to both migratory and invasive activities of OSCC cells, transwell migration and invasion assays were carried out after co-cultivation with each transfected-fibroblasts. YAPS127A fibroblasts induced higher cell motility of OSCC than WT-YAP fibroblasts or empty vector-fibroblasts (Fig 5F). Similarly, YAPS127A fibroblasts induced higher invasive activity than the wild type or the control cells (Fig 5G). To ascertain that YAP plays a critical role in OSCC invasiveness, two types of siRNA targeting YAP were used (Fig 6A). Subsequently, the effects of siRNAs on YAP nuclear localization were observed by using 200nM siYAPs. Both types of siRNA targeting YAP dramatically reduced nuclear YAP, whereas cytoplasmic YAP was still remained (Fig 6B). To examine the effect of matrix remodeling on gels by silencing YAPs fibroblasts, we

co-cultured hTERT-hNOFs with OSCC cells (Fig 4E and 4F). Also, the cell size was reduced by the treatment of Y27362 or Lat.A (Fig 4E and 4G). To support these results, phalloidin (F-actin) expression and YAP distribution was checked by immunofluorescence in NOF and CAFs (S3 Fig). As results, YAP was mostly distributed at cytoplasm in NOF, whereas YAP was localized at the nucleus in CAFs with distinct stress fibers (S3A and S3B Fig). The cell size of CAFs was larger than that of NOF, even this result was not statistically significant (S3C Fig).
Cytoskeletal alteration by RhoA-YAP signaling in stromal fibroblasts

A

Empty vector  YAP1 WT  YAP5127A

B

Empty vector  WT-YAP1  YAP5127A

YAP

p-YAP (S127)

α-SMA

β-actin

C

WT-YAP1

YAP1 WT

YAP5127A

D

Area of gel contraction (µm²)

Empty  WT-YAP  YAP5127A

*p=0.049

E

Young's Modulus (Pa)

Empty  WT-YAP  YAP5127A

F

Empty vector  YAP1 WT  YAP5127A

YD10B

YD38

G

Empty vector  YAP1 WT  YAP5127A

YD10B

YD38
performed contraction assay and roughness test of gels. As results, siYAPs-transfected fibroblasts showed less contraction and less rough surface of gels than siCont-transfected fibroblasts, even though it is not statistically significant (S5A and S5B Figs), making it permissive to OSCC cell invasion. Consequently, knockdown of YAP significantly reduced the number of invading OSCC cells that it shows to 6.00- / 7.02- fold decrease in YD10B cells and to 2.83- / 3.75- fold decrease in YD38 cells, compare with OSCC cells grown with siCont-transfected fibroblasts (Fig 6D, 6E and 6F). These results are independent on reduced cell proliferation showing that knockdown of YAP showed 1.23- fold and 1.22- fold decreased cell proliferation, compared with siCont-transfected fibroblasts, which data were not significant (Fig 6C).

Discussion

For this study, immortalized human normal oral fibroblasts (hTERT-hNOFs) were used to obtain repeatable in vitro results. Following co-culture with OSCC cells, the hTERT-hNOFs showed biologically identical characteristics with CAFs, and the functionally enhanced invasiveness of OSCC cells. These results suggest that hTERT-hNOFs can substitute for CAFs by co-culture with OSCC cells. In spite of hTERT-overexpression in fibroblasts, the fibroblasts showed a senescent phenotype after co-culture with OSCC cells. It might be triggered by stress from stimuli derived from OSCC cells. Stress-induced senescence cannot be prevented by hTERT-mediated telomere elongation and is triggered not only by shortening telomere, but also by nonspecific genome-wide DNA damage[34,35].

RhoA-ROCK, which could induce stress fiber formation with Rho GTPase family, is implicated in CAF-mediated remodeling of tumor microenvironment[25,26,31]. In our current study, we verified that RhoA mRNA and protein expression increased in hTERT-hNOFs by co-culturing with OSCC cells. Enlarged cell size and formation of stress fibers were interrupted by RhoA-ROCK inhibitor, supporting that RhoA-ROCK signaling could contribute to cytoskeletal alteration in CAFs.

YAP activity is dependent on its distribution; nuclear localization induces several growth factors via binding to different transcription factors, such as p73, RUNX2 and TEADs[32,36]. Conversely, cytoplasmic localization indicates the inactivated form, due to Ser127 phosphorylation, leading to its cytoplasmatic retention[32,33]. In our study, YAP was mainly localized in the nucleus and the expression of CTGF, direct target gene of YAP and TEADs, was increased in co-cultured hTERT-hNOFs with OSCC cells. In addition, nuclear distribution of YAP was translocated to the cytoplasm by inhibitors (Y27632 and Lat.A) in co-cultured hTERT-hNOFs with OSCC cells, confirming that YAP distribution can be regulated by RhoA-ROCK signaling and cytoskeleton organization.
Cytoskeletal alteration by RhoA-YAP signaling in stromal fibroblasts

A

| siYAP#1 | siYAP#2 |
|---------|---------|
| siCont  | 100     | 200     |
| YAP     |         |
| GAPDH   |         |

B

| Cytoplasm | Nuclear |
|-----------|---------|
| Cont      | Cont    |
| siCont    | siYAP#1 |
| siYAP#1   | siYAP#2 |
| YAP       |         |
| Lamin B1  |         |
| β-tubulin |         |

C

Day 0

Day 3

Cell number x10^6

D

hTERT-hNOFs

E

siCont + YD10B

siYAP#1 + YD10B

siYAP#2 + YD10B

Invading cells

F

siCont + YD38

siYAP#1 + YD38

siYAP#2 + YD38

Invading cells

*P = 0.049
To search the role of nuclear YAP-localized fibroblasts in cancer progression, a YAP active-mutant (YAPS127A) was generated. As a result, the gel contractility and stiffness increased with enlarged cellular size in YAPS127A fibroblasts. These results correspond to the reports that nuclear YAP as well as RhoA-ROCK affect cytoskeletal reorganization via RhoA-YAP circular loops[33,37].

Regarding that the increased gel contractility and tissue stiffness may act as significant tumor promoters[38], we observed migratory and invasive capacity, resulting in enhanced invasiveness of OSCC cells when co-cultured with YAPS127A fibroblasts. Matrix stiffness accompanies epithelial malignancy with tissue fibrosis and promotes tumor invasion by enhancing integrin-dependent mechanotransduction[39]. Given the data that YAP of fibroblasts play a critical role in invasiveness through modulating matrix structure[40,41], we examined the invasiveness by YAP-silencing in fibroblasts, revealing the reduced invasiveness in OSCC cells along with ECM rearrangement. Taken together, we can extrapolate that remodeling matrix structure by YAP-silencing may be a novel promising target for cancer therapy. Currently, CAFs-targeting cancer therapy has been limited to inhibit signaling molecules expressed in CAFs or cancer cells-CAFs interaction[19,42]. In the near future, the novel trial targeting matrix remodeling can be emerged.

In summary, we demonstrated that CAFs showed cytoskeletal alteration via RhoA-ROCK and increased nuclear YAP localization. Consequently, YAP activity of fibroblasts could remodel matrix organization and increase the matrix stiffness, in turn, promote the migration and invasion of OSCC cells. Thus, targeting cytoskeletal alterations in CAFs might be a spotlight in novel therapeutic approaches designed to modulate mechanical behaviors of CAF that contribute to OSCC invasiveness.

Supporting information

S1 Fig. Comparison of p16 and Ki67 expression in hTERT-hNOFs between co-cultured with HEK and with OSCC cells. All immunofluorescence representative pictures were shown on hTERT-hNOFs co-cultured with HEK (Upper panels), YD10B OSCC cells (Middle panels) and YD38 OSCC cells (Lower panels) for 3 days. DAPI(blue), Ki67(green) and p16(red) was stained, Scale bar, 50μm. Each bar graph indicates that Ki67 positive cells are represent as green, dual positivity of Ki67 and p16 as purple and p16 positivity as red for quantification. The number of positive cells was normalized by dividing the number of total cells, respectively, and presented as % of Ki67, Ki67+p16 and p16 positive cells. The results are shown as mean value ± SD (n = 3).

S2 Fig. hTERT-hNOFs have characteristics of senescent phenotype adjacent to oral cancer cells. (A) SA-β-Gal assay was performed and representative microscopic pictures (a) monocultured hTERT-hNOFs, hTERT-hNOFs, co-cultured with OSCC cells, including (b) YD10B, (c) YD38, (d) YD9 and (e) HSC2 are shown at 72 h (magnification: 200X, scale bar: 500 μm). The quantification of SA-β-Gal positive cells was normalized by dividing the number of total cells and presented as % of SA-β-Gal positive cells. The results are shown as mean value ± SD.
(n = 3) (*p < 0.05; Mann Whitney U test). (B) Representative microscopic pictures of SA-β-Gal positive cells in (a) mono-cultured hTERT-hNOFs, (b) hTERT-hNOFs co-cultured with HEK, (c) hTERT-hNOFs co-cultured with OSCC YD10B cells and (d) YD38 cells at 72 h (magnification: 200X, scale bar: 500 μm). Enlarged images are shown in the bottom of each left panel. The number of SA-β-Gal positive cells was normalized by dividing the number of total cells and presented as % of SA-β-Gal positive cells. The results are shown as mean value ± SD (n = 3) (*p < 0.05; Mann Whitney U test).

S3 Fig. F-actin assembly and YAP nuclear localization between NOF and CAFs. (A) All immunofluorescence microscopy experiments were performed on cultured cell after 3 days. DAPI(blue), Phalloidin(red) and Merged staining are shown in mono-cultured hTERT-hNOF (first panels) and hTERT-hNOF co-cultured with HEK (second panels), YD10B OSCC cell (third panels) and YD38 OSCC cell (fourth panels), Scale bar, 50 μm. The rectangular boxes are shown enlarged section to observe the YAP localization and F-actin assembly in detail. (B) The bar graph indicates the distribution of YAP in NOF and CAFs. It was analyzed by Image J software program (NOF, n = 9; CAFs, n = 23(CAF#1, n = 7; CAF#2, n = 7; CAF#3, n = 11)). (C) Cell size was measured by using ZEN 2012 software program (NOF, n = 9; CAFs, n = 23 (CAF#1, n = 7; CAF#2, n = 7; CAF#3, n = 11)) (*p < 0.05, ** p < 0.01, *** p < 0.001; Mann Whitney U test).

S4 Fig. The intensity of F-actin and cellular size in WT- and YAPS127A fibroblasts. (A) The mean intensity of Phalloidin was shown in WT- and YAPS127A fibroblasts. It was normalized by dividing the intensity of DAPI in cells. (B) Cell size was measured by using ZEN 2012 software program (WT-fibroblasts and YAPS127A fibroblasts, n = 15, respectively) (*p < 0.05; Mann Whitney U test).

S5 Fig. The rearrangement of ECM in siCont- and siYAPs fibroblasts. (A) The representative gel-contracting images were shown in siCont- and siYAPs fibroblasts. The bar graphs indicated average of gel size after contracting (B) The surface roughness (nm) by siCont- and siYAPs fibroblasts. it was measured by Atomic force microscopy(AFM). The experiments were performed in triplicate.

S1 Materials and Methods.

Author Contributions

Conceptualization: Do Kyeong Kim, Jin Kim.
Formal analysis: Do Kyeong Kim.
Investigation: Do Kyeong Kim.
Methodology: Do Kyeong Kim, Eun Kyoung Kim.
Project administration: Jin Kim.
Resources: Eun Kyoung Kim.
Supervision: Jin Kim.
Validation: Do Kyeong Kim.
Visualization: Do Kyeong Kim, Eun Kyoung Kim, Jin Kim.
Writing – original draft: Do Kyeong Kim, Jin Kim.
Writing – review & editing: Do Kyeong Kim, Da-Woon Jung, Jin Kim.

References
1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646–674. https://doi.org/10.1016/j.cell.2011.02.013 PMID: 21376230
2. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006; 6: 392–401. https://doi.org/10.1038NrC1877 PMID: 1652188
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407: 249–257. https://doi.org/10.1038/35025220 PMID: 11001068
4. Bae JY, Kim EK, Yang DH, Zhang X, Park YJ, Lee DY, et al. Reciprocal interaction between carcinoma-associated fibroblasts and squamous carcinoma cells through interleukin-1alpha induces cancer progression. Neoplasia. 2014; 16: 928–938. https://doi.org/10.1016/j.neo.2014.09.003 PMID: 25425967
5. Jung DW, Che ZM, Kim J, Kim K, Kim KY, Williams D, et al. Tumor-stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7. Int J Cancer. 2010; 127: 332–344. https://doi.org/10.1002/ijc.25060 PMID: 19937793
6. Hassona Y, Cirillo N, Lim KP, Herman A, Mellone M, Thomas GJ, et al. Progression of genotype-specific oral cancer leads to senescence of cancer-associated fibroblasts and is mediated by oxidative stress and TGF-beta. Carcinogenesis. 2013; 34: 1286–1295. https://doi.org/10.1093/carcin/bgt035 PMID: 23358854
7. Prime SS, Cirillo N, Hassona Y, Lambert DW, Paterson IC, Mellone M, et al. Fibroblast activation and senescence in oral cancer. J Oral Pathol Med. 2016. https://doi.org/10.1111/jop.12456 PMID: 27237745
8. Ohlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014; 211: 1503–1523. https://doi.org/10.1084/jem.20140692 PMID: 25071162
9. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, et al. Oncogene-induced senescence relayed by a interleukin-dependent inflammatory network. Cell. 2008; 133: 1019–1031. https://doi.org/10.1016/j.cell.2008.03.039 PMID: 18555778
10. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman JN, Chiavarina B, et al. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle. 2010; 9: 2423–2433. https://doi.org/10.4161/cc.9.12.12048 PMID: 20562526
11. Wheaton K, Sampsel K, Boisvert FM, Davy A, Robbins S, Riabowol K. Loss of functional caveolae during senescence of human fibroblasts. J Cell Physiol. 2001; 187: 226–235. https://doi.org/10.1002/jcp.1071 PMID: 11268002
12. Procopio MG, Laszlo C, Al Labban D, Kim DE, Bordignon P, Jo SH, et al. Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nat Cell Biol. 2015; 17: 1193–1204. https://doi.org/10.1038/ncb3228 PMID: 26302407
13. Corver WE, Ter Haar NT, Fleuren GJ, Oosting J. Cervical carcinoma-associated fibroblasts are DNA diploid and do not show evidence for somatic genetic alterations. Cell Oncol (Dordr). 2011; 34: 553–563. https://doi.org/10.1007/s13402-011-0061-5 PMID: 22042555
14. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 2012; 13: e178–185. https://doi.org/10.1016/S1470-2045(11)70335-7 PMID: 22469128
15. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest. 2006; 116: 1955–1962. https://doi.org/10.1172/JCI26592 PMID: 16794736
16. Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shpilts M, et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet. 2008; 40: 650–655. https://doi.org/10.1038/ng.117 PMID: 18408720
17. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 2009; 15: 21–34. https://doi.org/10.1016/j.ccr.2008.12.004 PMID: 19111878
18. Togo S, Polanska UM, Horimoto Y, Orimo A. Carcinoma-associated fibroblasts are a promising therapeutic target. Cancers (Basel). 2013; 5: 149–169. https://doi.org/10.3390/cancers5010149 PMID: 24216702

19. Kim EK, Moon S, Kim DK, Zhang X, Kim J. CXCL1 induces senescence of cancer-associated fibroblasts via autocrine loops in oral squamous cell carcinoma. PLoS One. 2018; 13: e0188847. https://doi.org/10.1371/journal.pone.0188847 PMID: 29360827

20. Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003; 9: 1639–1647 PMID: 12738716

21. Narra K, Mullins SR, Lee HO, Strzemkowski-Brun B, Magalon K, Christiansen VJ, et al. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007; 6: 1691–1699 PMID: 18032900

22. Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci U S A. 2007; 104: 3460–3465. https://doi.org/10.1073/pnas.0611660104 PMID: 17307870

23. Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov. 2012; 11: 790–811. https://doi.org/10.1038/nrd3810 PMID: 23006866

24. Illeperuma RP, Park YJ, Kim JM, Bae JY, Che ZM, Son HK, et al. Immortalized gingival fibroblasts as a cytotoxicity test model for dental materials. J Mater Sci Mater Med. 2012; 23: 753–762. https://doi.org/10.1007/s10856-011-4473-6 PMID: 22071981

25. Illeperuma RP, Kim DK, Park YJ, Son HK, Kim JY, Kim J, et al. Areca nut exposure increases secretion of tumor-promoting cytokines in gingival fibroblasts that trigger DNA damage in oral keratinocytes. Int J Cancer. 2015; 137: 2545–2557. https://doi.org/10.1002/ijc.29636 PMID: 26076896

26. Lee EJ, Kim J, Lee SA, Kim EJ, Chun YC, Ryu MH, et al. Characterization of newly established oral cancer cell lines derived from six squamous cell carcinoma and two mucoepidermoid carcinoma cells. Exp Mol Med. 2005; 37: 379–390. https://doi.org/10.1038/emm.2005.48 PMID: 16264262

27. Wada K, Itoga K, Okano T, Yonemura S, Sasaki H. Hippo pathway regulation by cell morphology and stress fibers. Development. 2011; 138: 3907–3914. https://doi.org/10.1242/dev.070987 PMID: 21831922

28. Kumper S, Marshall CJ. ROCK-driven actomyosin contractility induces tissue stiffness and tumor growth. Cancer Cell. 2011; 19: 695–697. https://doi.org/10.1016/j.ccr.2011.05.021 PMID: 21665143

29. Varelas X. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development. 2014; 141: 1614–1626. https://doi.org/10.1242/dev.102376 PMID: 24715453

30. Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013; 15: 637–646. https://doi.org/10.1038/ncb2756 PMID: 23708000

31. Gorbunova V, Seluanov A, Pereira-Smith OM. Expression of human telomerase (hTERT) does not prevent stress-induced senescence in normal human fibroblasts but protects the cells from stress-induced apoptosis and necrosis. J Biol Chem. 2002; 277: 38540–38549. https://doi.org/10.1074/jbc.M202671200 PMID: 12140282

32. Naka K, Tachibana A, Ikeda K, Motoyama N. Stress-induced premature senescence in hTERT-expressing ataxia telangiectasia fibroblasts. J Biol Chem. 2004; 279: 2030–2037. https://doi.org/10.1074/jbc.M309457200 PMID: 14570874

33. Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008; 22: 1962–1971. https://doi.org/10.1101/gad.166408 PMID: 18579750

34. Zhang Y, Xie P, Wang X, Pan P, Wang Y, Zhang H, et al. YAP Promotes Migration and Invasion of Human Glioma Cells. J Mol Neurosci. 2018; 64: 262–272. https://doi.org/10.1007/s10856-011-4473-6 PMID: 29306996
38. Haage A, Schneider IC. Cellular contractility and extracellular matrix stiffness regulate matrix metalloproteinase activity in pancreatic cancer cells. FASEB J. 2014; 28: 3589–3599. https://doi.org/10.1096/fj.13-245613 PMID: 24784579

39. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; 139: 891–906. https://doi.org/10.1016/j.cell.2009.10.027 PMID: 19931152

40. Zhang Y, Xia H, Ge X, Chen Q, Yuan D, Chen Q, et al. CD44 acts through RhoA to regulate YAP signaling. Cell Signal. 2014; 26: 2504–2513. https://doi.org/10.1016/j.cellsig.2014.07.031 PMID: 25101858

41. Wang Z, Wu Y, Wang H, Zhang Y, Mei L, Fang X, et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci U S A. 2014; 111: E89–98. https://doi.org/10.1073/pnas.1319190110 PMID: 24367099

42. Ferrari N, Ranftl R, Chicherova I, Slaven ND, Moeendarbary E, Farrugia AJ, et al. Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts. Nat Commun. 2019; 10: 130. https://doi.org/10.1038/s41467-018-07967-0 PMID: 30631061